** Shares in French vaccines maker Valneva VLS.PA rise 3% after the group posted what brokerage Portzamparc deems "dynamic and satisfactory" Q1 results
** Group Q1 revenue increases 50% to 49.2 million euros ($55.9 million), with IXIARO sales rising 65.5% to 27.5 million euros
** "Valneva's Q1'25 results showed a solid start of the year, driven by the usual strong Ixiaro sales growth," says Van Lanschot Kempen
** "We feature Valneva as one of our top picks as we see a high likelihood of success, and at this depressed valuation, an attractive risk-reward into the event," says Van Lanschot Kempen
** The shares have gained about 37.7% YTD
($1 = 0.8805 euros)
(Reporting by Dimitri Rhodes)
((Dimitri.rhodes@thomsonreuters.com))